arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ZEVRA THERAPEUTICS, INC.

ZVRA
$11.31 ▼ -0.27 (-2.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
52 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Bullish
auto_awesome

Analytical Summary

ZEVRA THERAPEUTICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $669.1M
Dividend Yield —
Revenue Growth 53.3% ↘
Op. Margin 42.3%
ROIC 5.3% ↘
FCF / Share $0.28 ↗
Trailing P/E 80.8x
Price / Book 3.1x
FCF Yield 2.5%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Sep 23, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$39.66M
↑ +53.3% —
Net Income Profit after all expenses
$37.89M
— 0.0% —
Operating Margin Operating profit as % of sales
42.3%
↑ +166.1% 4th
FCF / Share Free cash flow per share
$0.28
↑ +171.8% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
41
Returns
97
Financial Health
43
Cash Quality ↑
21

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 52 quarters